ALK and chronic myelogenous leukemia, BCR-ABL1 positive: The thematic communities of the TKIs consist of C1 (NSCLC), C2 (targeted therapy), C3 (CML), C4 (HER2), C5 (pharmacokinetics), and C6 (ALK).